<DOC>
	<DOCNO>NCT01203267</DOCNO>
	<brief_summary>The purpose study evaluate pathological complete response ( pCR ) rate breast cancer patient treat weekly paclitaxel plus carboplatin preoperative regimen .</brief_summary>
	<brief_title>Weekly Paclitaxel Plus Carboplatin Preoperative Treatment Breast Cancer</brief_title>
	<detailed_description>Breast cancer lead cause cancer woman China . Preoperative chemotherapy treatment locally advance breast cancer become standard therapy . Results neoadjuvant trial show pathological complete response ( pCR ) independent predictor outcome . Paclitaxel introduce clinical practice early 1990s demonstrate good activity adjuvant metastatic setting . Platinum complex , like cisplatin carboplatin , active wide range solid tumor . Paclitaxel combine carboplatin show great activity ovarian nonsmall- cell lung cancer treatment . In addition , overall response rate paclitaxel plus carboplatin 53 % 62 % first-line treatment metastatic breast cancer . This study evaluate pCR rate weekly paclitaxel plus carboplatin preoperative treatment breast cancer patient .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Women age ≥ 18 year &lt; 70 year Karnofsky performance status ( KPS ) ≥ 70 At least one measurable disease accord RECIST . histologically confirm invasive breast cancer ( exclude inflammatory breast cancer ) , large operable ( T≥3 cm N01 ) locally advanced breast cancer ( T34N03 T04N23 ) Biopsy specimens available ER , PgR Her2 analysis Adequate bone marrow function : Neutrophil ≥ 1.5*109/L ; Hb ≥ 100g/L ; PLT ≥ 100*109/L An estimate life expectancy least 12 month Willing take biopsy neoadjuvant chemotherapy patient must accessible treatment followup Women potential childbearing must negative pregnancy test ( urine serum ) within 7 day drug administration agree use acceptable method birth control avoid pregnancy duration study Written inform consent accord GCP Prior systemic locoregional treatment breast cancer , include chemotherapy Metastatic breast cancer With history malignant tumor except uterine cervix cancer situ skin basal cell carcinoma Patients medical condition indicate intolerant neoadjuvant therapy relate treatment , include uncontrolled pulmonary disease , diabetes mellitis , severe infection , active peptic ulcer , coagulation disorder , connective tissue disease myelosuppressive disease inadequate liver function ( bilirubin &gt; 1.0 time upper normal limit [ UNL ] ALT and/or AST &gt; 1.5 UNL associate alkaline phosphatase &gt; 2.5 UNL ; inadequate renal function ( creatinine &gt; 1.0 time UNL case limit value , Creatinine clearance &lt; 60 ml/min ) Contraindication use dexamethasone History congestive heart failure , uncontrolled symptomatic angina pectoris , arrhythmia myocardial infarction ; poorly control hypertension ( systolic BP &gt; 180 mmHg diastolic BP &gt; 100 mmHg ) Has peripheral neuropathy ≥ grade 1 Patient pregnant breast feed Known severe hypersensitivity drug study Treatment investigational drug within 30 day begin study treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Breast Neoplasms</keyword>
	<keyword>Neoadjuvant</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Pathological Complete Remission</keyword>
</DOC>